Michael King
Stock Analyst at EF Hutton
(0.78)
# 3,860
Out of 4,910 analysts
117
Total ratings
34.15%
Success rate
-16.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael King
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLM Apollomics | Maintains: Buy | $1,100 → $650 | $5.97 | +10,787.77% | 4 | Apr 1, 2024 | |
| SONN Sonnet BioTherapeutics Holdings | Assumes: Buy | $1,179 | $4.57 | +25,703.06% | 7 | Aug 23, 2023 | |
| LTRN Lantern Pharma | Reiterates: Buy | $11 | $4.23 | +160.05% | 10 | Aug 10, 2023 | |
| BMEA Biomea Fusion | Reiterates: Buy | $32 | $1.85 | +1,629.73% | 11 | Jun 26, 2023 | |
| JSPR Jasper Therapeutics | Reiterates: Buy | $69 | $3.27 | +1,994.80% | 10 | Jun 12, 2023 | |
| COEP Coeptis Therapeutics Holdings | Assumes: Buy | $200 | $12.31 | +1,524.70% | 7 | May 25, 2023 | |
| HOWL Werewolf Therapeutics | Assumes: Buy | $8.3 | $1.39 | +497.12% | 6 | May 25, 2023 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Buy | $862 | $572.39 | +50.60% | 11 | May 1, 2023 | |
| EXEL Exelixis | Reiterates: Buy | $24 | $45.40 | -47.14% | 10 | Apr 28, 2023 | |
| AGEN Agenus | Reiterates: Buy | $166 | $6.07 | +2,634.76% | 8 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $42 | $9.57 | +338.87% | 5 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $304 | $326.13 | -6.79% | 2 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $123 → $116 | $14.24 | +714.61% | 6 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $3.33 | +209.31% | 2 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $39.71 | -39.56% | 1 | Mar 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,000 → $800 | $0.70 | +114,185.71% | 2 | Mar 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $46 | $26.99 | +70.43% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $98 → $96 | $40.55 | +136.77% | 6 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $0.69 | +5,121.17% | 1 | Jan 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.37 | +3,187.67% | 1 | Dec 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $31 | $12.36 | +150.91% | 2 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $33 → $36 | $575.42 | -93.74% | 2 | Nov 13, 2017 |
Apollomics
Apr 1, 2024
Maintains: Buy
Price Target: $1,100 → $650
Current: $5.97
Upside: +10,787.77%
Sonnet BioTherapeutics Holdings
Aug 23, 2023
Assumes: Buy
Price Target: $1,179
Current: $4.57
Upside: +25,703.06%
Lantern Pharma
Aug 10, 2023
Reiterates: Buy
Price Target: $11
Current: $4.23
Upside: +160.05%
Biomea Fusion
Jun 26, 2023
Reiterates: Buy
Price Target: $32
Current: $1.85
Upside: +1,629.73%
Jasper Therapeutics
Jun 12, 2023
Reiterates: Buy
Price Target: $69
Current: $3.27
Upside: +1,994.80%
Coeptis Therapeutics Holdings
May 25, 2023
Assumes: Buy
Price Target: $200
Current: $12.31
Upside: +1,524.70%
Werewolf Therapeutics
May 25, 2023
Assumes: Buy
Price Target: $8.3
Current: $1.39
Upside: +497.12%
Regeneron Pharmaceuticals
May 1, 2023
Reiterates: Buy
Price Target: $862
Current: $572.39
Upside: +50.60%
Exelixis
Apr 28, 2023
Reiterates: Buy
Price Target: $24
Current: $45.40
Upside: -47.14%
Agenus
Mar 28, 2023
Reiterates: Buy
Price Target: $166
Current: $6.07
Upside: +2,634.76%
Feb 24, 2023
Reiterates: Buy
Price Target: $42
Current: $9.57
Upside: +338.87%
Feb 24, 2023
Reiterates: Buy
Price Target: $304
Current: $326.13
Upside: -6.79%
Feb 24, 2023
Maintains: Buy
Price Target: $123 → $116
Current: $14.24
Upside: +714.61%
Dec 16, 2022
Initiates: Buy
Price Target: $10
Current: $3.33
Upside: +209.31%
Mar 23, 2022
Initiates: Buy
Price Target: $24
Current: $39.71
Upside: -39.56%
Mar 11, 2022
Maintains: Buy
Price Target: $1,000 → $800
Current: $0.70
Upside: +114,185.71%
Mar 8, 2022
Maintains: Buy
Price Target: $43 → $46
Current: $26.99
Upside: +70.43%
Mar 3, 2022
Maintains: Buy
Price Target: $98 → $96
Current: $40.55
Upside: +136.77%
Jan 10, 2022
Initiates: Buy
Price Target: $36
Current: $0.69
Upside: +5,121.17%
Dec 23, 2021
Initiates: Buy
Price Target: $12
Current: $0.37
Upside: +3,187.67%
Nov 5, 2021
Maintains: Buy
Price Target: $25 → $31
Current: $12.36
Upside: +150.91%
Nov 13, 2017
Maintains: Market Outperform
Price Target: $33 → $36
Current: $575.42
Upside: -93.74%